Preclinical is not clinical of course, but being a pan-cancer treatment, not only for prostate cancer, and a novel immune therapy perspective, I would keep an eye on this!
"has generated an extensive preclinical dataset showing strong monotherapy efficacy across many tumor types. This efficacy is mediated by immunogenic cancer cell death and mobilization of the immune system, leading to durable responses in preclinical mouse models."